Courtney E. Bakan

TL;DR: It is demonstrated that CT-011, a novel anti-PD-1 antibody, enhances humanNK-cell function against autologous, primary MM cells, seemingly through effects on NK-cell trafficking, immune complex formation with MM cells and cytotoxicity specifically toward PD-L1(+) MM tumor cells but not normal cells.

TL;DR: It is shown that elotuzumab appears to induce activation of NK cells by binding to NK cell CS1 which promotes cytotoxicity against CS1(+) MM cells but not against autologous CS1 (+) NK cells.

TL;DR: It is suggested that IPH2101 is safe and tolerable at doses that achieve full inhibitory KIR saturation, and this approach warrants further development in MM.

TL;DR: Mechanistic, preclinical data support the use of a combination of IPH2101 and lenalidomide in a phase 2 trial for MM and support the importance of this signaling axis in the natural killer (NK) cell-versus-MM effect.

TL;DR: The data suggest that FLLL32 represents a lead compound that could serve as a platform for further optimization to develop improved STAT3 specific inhibitors for melanoma therapy.